Beyond Air, Inc. (XAIR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-15

Key Insights

Beyond Air has received a Nasdaq delisting notice due to falling below the $1 minimum bid price requirement. The company has requested a hearing to appeal this decision, which will stay any delisting action pending the panel's decision.
There is no guarantee the Nasdaq panel will grant Beyond Air's request for continued listing or that the company will be able to regain compliance with Nasdaq's listing requirements within any compliance period granted.
The company has acknowledged the risks and uncertainties associated with the delisting proceedings, which could have a significant impact on the stock if the company is ultimately delisted from Nasdaq.

Current Report Filed: 2026-04-10

Key Insights

Beyond Air has received a notification from Nasdaq that it no longer meets the $1.00 minimum bid price requirement for continued listing. This could result in the delisting of the company's stock from the exchange.
The company has a limited time frame to request a hearing with the Nasdaq Hearings Panel to appeal the delisting decision. The outcome of this appeal process is uncertain.
To regain compliance, Beyond Air is considering a reverse stock split, which could help it maintain its Nasdaq listing. However, there is no guarantee that this action will be successful.

Quarterly Report Filed: 2026-02-13

Key Insights

The company reported a significant decline in revenue and profitability over the past year, indicating potential operational challenges.
The company has entered into a securities purchase agreement to raise additional capital, which could help fund its ongoing operations and development efforts.
The company's acquisition of two subsidiaries, Beyond Cancer Ltd and NeuroNos Ltd, suggests a shift in its strategic focus towards new business areas.

Current Report Filed: 2026-02-13

Key Insights

Beyond Air, Inc. reported financial results for its third quarter ended December 31, 2025, indicating operational and financial updates for the company.
The company did not provide any information about material agreements, leadership changes, or earnings surprises in this 8-K filing.
Without additional details on the financial performance and operational updates, it is difficult to determine the overall significance of this filing for investors.

Current Report Filed: 2026-01-20

Key Insights

Beyond Air entered into a $5 million private placement offering with an institutional investor, issuing common stock, pre-funded warrants, and common warrants.
The company agreed to file a registration statement to register the resale of the shares issued in the private placement, with penalties for failure to do so.
The private placement included a 90-day restriction on additional share issuances by the company, as well as a 6-month restriction on certain variable rate transactions.

Current Report Filed: 2026-01-15

Key Insights

Beyond Air has entered into a binding letter of intent to sell its 85% ownership stake in NeuroNOS Ltd. to XTL Biopharmaceuticals Ltd. for a combination of XTL shares, cash, and milestone-based payments.
The divestment of NeuroNOS, a biotechnology company developing therapeutics for Autism Spectrum Disorder and neuro-oncology, could allow Beyond Air to focus on its core respiratory and pulmonary treatment pipeline.
The transaction terms, including the 19.9% equity stake in XTL, $1 million in cash, and up to $31.5 million in potential milestone payments, suggest this could be a favorable deal for Beyond Air.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.